Innate Pharma SA (FR:IPH) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Innate Pharma SA has announced its selection for the 2024 ASH Annual Meeting, highlighting their progress with lacutamab and the SAR443579 asset, developed in collaboration with Sanofi. These advancements reflect Innate’s commitment to delivering new cancer treatments, particularly for lymphomas with high unmet needs. The company’s innovative approach and strategic partnerships position it as a significant player in the biotech sector.
For further insights into FR:IPH stock, check out TipRanks’ Stock Analysis page.